Paraneoplastic Syndromes: Clinical Trials

15 trials for Paraneoplastic Syndromes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 5 recruiting, 2 unknown, 1 active not recruiting. 15 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 415Completed 6, Recruiting 5, Unknown 2, Active not recruiting 1, Not yet recruiting 1

Follow Paraneoplastic Syndromes: new trials by email Literature Review of Paraneoplastic Syndromes trials Research Report on Paraneoplastic Syndromes

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Osilodrostat, Placebo - Hypertension, Hypercortisolemia
Phase 4RecruitingRECORDATI GROUP632026-08-262026-11-02
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
Intervention 1: Adrenalectomy, Intervention 2: Semaglutide - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Phase 4RecruitingUniversity of Texas Southwestern Medical Center752026-03-052026-11-18
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone - Generalized Myasthenia Gravis, gMG
Phase 4RecruitingAlexion Pharmaceuticals, Inc.752026-03-042026-04-09
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Osilodrostat (Isturisa) - Mild Autonomous Cortisol Secretion (MACS)
Phase 4RecruitingJohns Hopkins University102026-02-022026-10-23
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Rozanolixizumab - Myasthenia Gravis
Phase 4Active not recruitingUCB Biopharma SRL402025-12-012026-10-29
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
Efgartigimod - Myasthenia Gravis, Generalized
Phase 4RecruitingCentre Hospitalier Universitaire de Nice502025-09-192026-09-03
Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
Telitacicept - Myasthenia Gravis, Autoimmune Diseases
Phase 4Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical University302024-12-012024-12-09
Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis
Pyridostigmine, Placebo oral capsule - Myasthenia Gravis
Phase 4UnknownUniversity of Aarhus442018-04-092018-04-27
A Randomized Clinical Trial About Use of 3D Laparoscopy Versus 2D Laparoscopy in Adrenal Surgery
laparoscopic adrenalectomy - Adrenal Mass, Adrenal Adenoma
Phase 4CompletedUniversity of Palermo3502018-01-012024-08-28
Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism
Synacthen infusion during adrenal venous sampling - Primary Aldosteronism
Phase 4UnknownCharles University, Czech Republic402011-03-012014-05-01
Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis
Prednisone - Azathioprine - Myasthenia Gravis
Phase 4CompletedAssistance Publique - Hôpitaux de Paris1182009-06-012017-10-13
Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis
IVIG, PLEX - Myasthenia Gravid
Phase 4CompletedUniversity Health Network, Toronto872007-03-012010-08-11
Treatment of Zollinger-Ellison Syndrome With Prevacid
Lansoprazole (Prevacid) - Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia
Phase 4CompletedCharles Mel Wilcox, MD722003-03-012012-10-30
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
Mitoxantrone - Neuromyelitis Optica, Myelitis, Transverse
Phase 4CompletedState University of New York at Buffalo52001-08-012020-12-28
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
interferon beta 1a 30 ug IM once weekly - Multiple Sclerosis, Optic Neuritis
Phase 4CompletedBeth Israel Deaconess Medical Center1552001-02-012017-09-06

Narrower conditions

Myasthenia Gravis (7)  ·  ACTH Syndrome, Ectopic (5)  ·  Hypertension (3)  ·  Cushing Syndrome (2)  ·  Myelitis, Transverse (2)  ·  Adrenal Gland Neoplasms (1)  ·  Adrenal Hyperplasia, Congenital (1)  ·  Adrenal Insufficiency (1)  ·  Adrenal incidentaloma (1)  ·  Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Cerebellar Diseases (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Hyperaldosteronism (1)  ·  Insulin Resistance (1)

Broader conditions

Neoplasms (15)  ·  Neoplasms by Site (11)  ·  Immune System Diseases (9)  ·  Nervous System Diseases (9)  ·  Nervous System Neoplasms (9)  ·  Neurodegenerative Diseases (9)  ·  Paraneoplastic Syndromes, Nervous System (9)  ·  Autoimmune Diseases (8)  ·  Autoimmune Diseases of the Nervous System (8)  ·  Endocrine System Diseases (7)  ·  Neuromuscular Diseases (7)  ·  Neuromuscular Junction Diseases (7)  ·  Adrenal Gland Diseases (6)  ·  Paraneoplastic Endocrine Syndromes (6)

Interventions

Osilodrostat (2)  ·  Prednisone (2)  ·  Pyridostigmine Bromide (2)  ·  Immunoglobulins, Intravenous (1)  ·  Interferon beta-1a (1)  ·  Lansoprazole (1)  ·  Mitoxantrone (1)  ·  Prednisolone (1)  ·  efgartigimod alfa (1)  ·  ravulizumab (1)  ·  rozanolixizumab (1)  ·  telitacicept (1)

Sponsors

Alexion Pharmaceuticals, Inc. (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Centre Hospitalier Universitaire de Nice (1)  ·  Charles Mel Wilcox, MD (1)  ·  Charles University, Czech Republic (1)  ·  First Affiliated Hospital of Wenzhou Medical University (1)  ·  Johns Hopkins University (1)  ·  RECORDATI GROUP (1)  ·  State University of New York at Buffalo (1)  ·  UCB Biopharma SRL (1)  ·  University Health Network, Toronto (1)  ·  University of Aarhus (1)  ·  University of Palermo (1)  ·  University of Texas Southwestern Medical Center (1)

Countries

United States (6)  ·  Canada (2)  ·  France (2)  ·  Italy (2)  ·  China (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Germany (1)  ·  Japan (1)

Top investigators

Amir Hamrahian, MD (1)  ·  Bianca Weinstock-Guttman, M.D. (1)  ·  C. Mel Wilcox, M.D. (1)  ·  David Barth, MD (1)  ·  Irina Bancos, MD (1)  ·  Jan LS Thomsen, MD (1)  ·  Jiri Ceral, MD (1)  ·  Revere P Kinkel, MD (1)  ·  Tarek Sharshar, MD PH (1)  ·  Vera Bril, BSc, MD, FRCPC (1)

Results publications

PMID 15645403, PMID 16831964, PMID 17767471, PMID 18507843, PMID 19581810, PMID 21073392, PMID 21193359, PMID 26708842, PMID 27454103, PMID 28887710, PMID 29510982, PMID 30817193, PMID 31206616, PMID 33555314, PMID 35220871, PMID 3536461, PMID 35817047, PMID 36952249, PMID 37318239, PMID 37801655, PMID 39062179, PMID 39086899, PMID 6135282

NIH funding

2025 (1), K23DK142038 (1)